A Food and Drug Administration advisory panel has voted to ease measures that limit patient access to the diabetes pill Avandia. Many panelists, however, said precautions are still needed. As a result, the panel is recommending that patients be required to sign a waiver before taking the medication. Physicians are already required to sign papers indicating they understand possible medication-related risks. While a quarter million people were taking Avandia in 2010, that figure has since dwindled to less than 4,000. Reports linking Avandia to heart attacks spurred the drop-off.
Next Article in Products
- Report predicts 'bright future' for nursing homes — with caveats
- Lawmakers target nursing homes' biggest payer for fraud reduction
- The skilled care sector may be doomed. What else is new?
- Louisiana notifying 16K nursing home residents they could be forced out in funding fight
- Congress looks ready to ignore MedPAC, make its own Medicare reform
- HCR ManorCare files for bankruptcy, setting up purchase by Quality Care Properties
- CMS: Schedule up in the air for new RCS-1 therapy classification system
- More empty beds: Medicare patients further weaken demand for skilled nursing
- NAB is making major CE changes. Register now or suffer later.
- Per-bed SNF price plummets in 2017; NIC's cross-sector collaboration to support industry
- Workplace engagement crushers: 5 Easy Ways to undermine employee engagement
- The top 11 questions all operators still have to answer in 2018
- Kindred Healthcare seeks review of $10M denial for dual-eligible patients
- CMS proposes regulatory cuts for states with high Medicaid Advantage rates
- Judge rules nursing home residents with mental health, prison records can stay in the suburbs